Handelsavisen
prelaunch
Companies Healthcare 4506.T
45
4506.T Tokyo Stock Exchange Pharmaceuticals

4506.T

¥1 459,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
7,2 %
ROE
14,0 %
Net margin
5,9 %
Debt / equity
1,85
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, generating revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.

Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
HOLD6 analysts
3 buy2 hold1 sell
Avg 12m price target2 180,00

Analyst recommendations

6 analysts · consensus Hold
Buy3
Hold2
Sell1
12-month price target
2 180,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
6 analysts · indicative
Ownership
not yet wired
Profitability
14,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4506.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4506.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, generating revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a capital structure with a debt-to-equity ratio of 1.85, indicating a relatively high level of leverage. Its liquidity position is characterized by a current ratio of 1.05, suggesting limited short-term liquidity cushion. Free cash flow of 36.16 billion JPY supports operational flexibility, but the company's long-term debt of 314.25 billion JPY raises concerns about long-term solvency.

    Profitability metrics show a return on equity of 13.95%, which is strong, but the return on assets of 3.18% is relatively low, indicating inefficient use of assets to generate returns. Gross profit of 245.50 billion JPY supports a solid margin, but operating income of 28.80 billion JPY and net income of 23.63 billion JPY suggest pressure from operating expenses and taxes.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks.

    Outlook for the current fiscal year shows a modest growth trajectory, with revenue expected to remain stable. Analysts project a mean price target of 2,180.00 JPY, with a median of 2,200.00 JPY, indicating a generally positive but cautious sentiment.

    Risk factors include a medium liquidity risk due to the current ratio and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no significant dilution potential in the near term.

    Recent events include analyst estimates and price targets, with a mean recommendation of 2.67, indicating a mixed outlook. No recent filings or transcripts have been disclosed that would significantly alter the company's strategic direction.

    Key takeaways
    • The company has a strong return on equity but a weak return on assets, indicating asset inefficiency.
    • High leverage and a negative net cash position raise concerns about long-term solvency.
    • Analysts project a cautious outlook with a mean price target of 2,180.00 JPY.
    • The company's lack of geographic and segment diversification increases exposure to regional and business-specific risks.
    • Liquidity is limited, with a current ratio of 1.05 and no significant dilution risk in the near term.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥1 459,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    ¥169.48B
    Net cash
    -¥291.13B
    Current ratio
    1.1
    Debt / equity
    1.9
    ROA
    3.2%
    ROE
    14.0%
    Cash conversion
    14.0%
    CapEx / revenue
    -3.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    235,86
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    6
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-06 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate235,86
    Revenueno estimateno estimate439,5B JPY
    Operating incomeno estimateno estimateno estimate
    Full-year consensus mean (period as reported by source) · consensus in JPY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution6 analysts
    Strong buy1
    Buy2
    Hold2
    Sell0
    Strong sell1
    12-month price target¥2 180,00 · Median ¥2 200,00
    Low ¥1 500,00High ¥2 700,00
    EPS surprise
    −74,8 %
    reported vs consensus · miss
    Revenue surprise
    −9,3 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low¥1 500,00
    Mean¥2 180,00
    Median¥2 200,00
    High¥2 700,00
    Spot¥1 459,00
    +49.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin7,2 %Above median
    Net Margin5,9 %Above median
    ROE14,0 %Above P75
    Capex / Rev-3,3 %Above median
    D/E1,85Bottom quartile
    Cash Conv0,14Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 4506.T Market data — financials · 2026-05-26
    • Sumitomo Pharma Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4506.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage